Clinical trials and post-marketing surveillance have drawn attention to the increased risk of genitourinary infections and volume depletion accompanying the use of SGLT2 inhibitors in the presence of diabetes [41]. This evidence concerns the gene SLC5A2 and diabetes mellitus.